Literature DB >> 33826026

Symptoms and signs of parotid tumors and their value for diagnosis and prognosis: a 20-year review at a single institution.

Yuko Inaka1, Ryo Kawata2, Shin-Ichi Haginomori1, Tetsuya Terada1, Masaaki Higashino1, Shuji Omura1, Yusuke Kikuoka1.   

Abstract

BACKGROUND: Detailed clinical features other than parotid mass have not been investigated in detail for parotid tumors. Symptoms and signs are useful for the differentiation of benign versus malignant, and may also be of value to determine the grade of malignancy and histological type as well as the assessment of prognosis.
METHODS: We reviewed symptoms and signs of 965 patients with benign tumors and 200 patients with malignant tumors. Symptoms and signs included pain/tenderness, adhesion to surrounding tissues, and facial nerve palsy. We reviewed the incidence in benign and malignant tumors, in histological type of benign tumors, and in grade and histology of malignant tumors. For each symptom or sign, covariates were analyzed, and their correlation with the prognosis was investigated.
RESULTS: The incidence of symptoms and signs was significantly higher in malignant than benign tumors, and more frequent in higher grade of malignancy. Facial nerve palsy was observed in 18.0% of malignant tumor cases, while none occurred in benign tumor cases. Pain/tenderness was more commonly observed in adenoid cystic carcinoma, while adhesion to surrounding tissues and facial nerve palsy were most frequently noted in salivary duct carcinoma. The prognosis of patients with these symptoms and signs was significantly poor.
CONCLUSION: A detailed investigation of symptoms and signs in parotid gland tumors is the first step that leads to the diagnosis of malignant tumors. Symptoms and signs are also useful for estimating the grade of malignancy and histological type, and they are important information for predicting prognosis.

Entities:  

Keywords:  Benign tumor; Grade of malignancy; Malignant tumor; Parotid tumor; Symptoms/signs

Mesh:

Year:  2021        PMID: 33826026     DOI: 10.1007/s10147-021-01901-3

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  4 in total

1.  BDNF/TRKB axis provokes EMT progression to induce cell aggressiveness via crosstalk with cancer-associated fibroblasts in human parotid gland cancer.

Authors:  Kazumasa Moriwaki; Masaki Wada; Hiroko Kuwabara; Yusuke Ayani; Tetsuya Terada; Masaaki Higashino; Ryo Kawata; Michio Asahi
Journal:  Sci Rep       Date:  2022-10-20       Impact factor: 4.996

2.  A retrospective study of parotid gland tumors at a single institution.

Authors:  Shiori Suzuki; Nobuyuki Bandoh; Takashi Goto; Akinobu Kubota; Akihiro Uemura; Michihisa Kono; Ryosuke Sato; Ryuhei Takeda; Shota Sakaue; Tomomi Yamaguchi-Isochi; Hiroshi Nishihara; Hidehiro Takei; Yasuaki Harabuchi
Journal:  Oncol Lett       Date:  2022-05-13       Impact factor: 3.111

3.  Establishment and Validation of Prognostic Nomograms for Patients With Parotid Gland Adenocarcinoma Not Otherwise Specified: A SEER Analysis From 2004 to 2016.

Authors:  Zi-Meng Wang; Zuo-Lin Xiang
Journal:  Front Surg       Date:  2022-01-11

4.  Parotid metastases from primary lung cancer: Case series and systematic review of the features.

Authors:  Rulan Wang; Ting Wang; Qinghua Zhou
Journal:  Front Oncol       Date:  2022-08-25       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.